TechTimes · Jun 2026
Coverage of Synchron’s planned pivotal clinical trial in 2026 and the significance of the trial for potential FDA approval.
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Synchron is a neurotechnology company pioneering interventional brain-computer interfaces (BCIs). Its first product, Stentrode™, is a minimally invasive implantable BCI delivered via the jugular vein that aims to restore communication, independence, and agency for people living with paralysis.
Primary product
Stentrode™ implantable brain-computer interface (BCI)
Founded
2016
Headquarters
Brooklyn, New York, United States
Team size
70-80
Industry
Medical Equipment Manufacturing
Sub-industry
Neurotechnology / implantable brain-computer interfaces
Offices
New York City (Soho, cognition lab)
Open Positions
0 jobs at Synchron
No open positions
Check back later for new openings